AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best low cost stocks to buy under $5. On March 3, AtaiBeckley announced a successful End-of-Phase 2 meeting with the FDA regarding BPL-003, a proprietary intranasal formulation of mebufotenin benzoate for treatment-resistant depression/TRD. The FDA indicated support for the proposed Phase 3 program, providing constructive feedback on the design and safety database requirements for this chronic indication.

This milestone follows the Breakthrough Therapy designation granted in late 2025, with the company remaining on track to initiate the Phase 3 program in the second quarter of 2026. The Phase 3 program consists of two parallel pivotal studies, ReConnection 1 and ReConnection 2, followed by a 52-week open-label extension to assess long-term safety and individualized retreatment. ReConnection 1 will evaluate single doses of 8 mg and 4 mg against a placebo to characterize the dose-response relationship, while ReConnection 2 will investigate a two-dose induction model on Day 1 and Day 15.

Designed to fit within existing interventional psychiatry workflows, BPL-003 aims to offer a rapid and durable treatment option with an approximately two-hour in-clinic experience. AtaiBeckley Inc. (NASDAQ:ATAI) believes that this model addresses significant barriers for patients and providers by requiring only a few treatments per year.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the US, Germany, and Canada.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Most Promising Micro-Cap Stocks According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.